Clinical development failure
The company is still preclinical/early clinical, so program outcomes are highly uncertain.
- Scope
- EDIT-401 and other programs may never reach approval.
- Materiality
- high
Editas Medicine, Inc.
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms. Its work is centered on preclinical and early clinical programs, plus collaborations and licensing deals that generate most of its current revenue while it advances therapies for genetic and other serious diseases.
−381,9 %
−395,0 %
+25,4 %
3.54
3.54
| % | |
|---|---|
| Therapeutic gene-editing programs | 20% Preclinical and early clinical CRISPR medicines designed to treat serious genetic and other diseases. |
| Collaborations and milestones | 70% Revenue from partner-funded development work, option packages, and milestone payments, mainly with BMS. |
| Licensing fees | 10% Annual and upfront license fees from technology access agreements such as the Vertex license. |
Editas does not sell approved medicines today; its economic customers are pharmaceutical partners, licensees, and...
- Pharmaceutical collaboration partnersprimary
Large biopharma companies that pay for access to Editas' CRISPR platforms, development work, and option rights.
- Licensees of gene-editing IPprimary
Companies such as Vertex that pay upfront or annual fees to use Editas-linked intellectual property and technology.
- Future treating physicians and patientsemerging
If programs are approved, hospitals, specialists, and patients in rare disease and liver indications would use the medicines.
- Research collaboratorssecondary
Academic and industry partners that use Editas' platform technologies in partnered discovery and development programs.
Editas is headquartered in the United States and conducts most of its research, development, and corporate activity...
- •Headquartered and primarily operated in the United States
- •Revenue is driven by U.S.-based collaboration and license agreements
- •No owned manufacturing facilities; relies on third parties
- •European patent disputes create foreign legal exposure
- •Future commercialization would likely require global partner reach
Editas is shifting toward a narrower, capital-efficient pipeline built around EDIT-401 and other preclinical...
01
Advance EDIT-401 into clinical developmentshort-term
The company needs a lead program to create future product value and validate its gene-editing platform.
02
Expand partnered and licensed revenueshort-term
Collaboration and license income currently funds operations and reduces dependence on product sales.
03
Strengthen delivery and platform capabilitiesmedium-term
Effective delivery is a key bottleneck in in vivo gene editing and can improve program success rates.
04
Preserve capital and simplify operationsshort-term
As a preclinical biotech with no product sales, runway management is critical to avoid dilution and program delays.
Editas faces the classic risks of an early-stage gene-editing biotech: clinical failure, regulatory delay, and...
Intellectual property disputes
Some in-licensed patents face priority and validity challenges in the U.S. and Europe.
- Scope
- Could force licensing, delay programs, or prevent commercialization.
- Materiality
- high
Funding and liquidity risk
The company does not expect meaningful recurring product revenue in the near term.
- Scope
- May need additional capital before commercialization.
- Materiality
- high
Partner concentration
Substantially all current revenue is expected from Vertex, BMS, and future collaborations.
- Scope
- Loss or slowdown of a partner would reduce revenue and runway.
- Materiality
- high
Competition in gene editing
Many large and well-funded biotech and pharma companies are pursuing similar indications.
- Scope
- Competitors may reach the market first or develop better therapies.
- Materiality
- medium
Revenue recognition for collaborations
Affects reported revenue timing and deferred revenue balances
Deferred revenue
Impacts future revenue recognition and balance sheet liabilities
Restructuring and impairment charges
Can materially distort operating expense trends and comparability
License fee accounting
Creates recurring revenue that is not tied to product sales
Edesa Biotech, Inc.
EDSA · Pharmaceutical Preparations
Sedana Medical
SEDANA.ST · Health Care
Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals.
Modular Medical, Inc.
MODD · Surgical & Medical Instruments & Apparatus
BECTON DICKINSON & CO
BDX · Surgical & Medical Instruments & Apparatus
Becton, Dickinson and Company (BD) is a U.S.-based medical technology company with roots dating back to 1897 and incorporation in 1906.
Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances)
Inhibitor Therapeutics, Inc.
INTI · Pharmaceutical Preparations
: 28.4.2026